Glucose-induced CRL4COP1-p53 Axis Amplifies Glycometabolism to Drive Tumorigenesis.

Yang Su,Yifan Luo,Peitao Zhang,Hong Lin,Weijie Pu,Hongyun Zhang,Huifang Wang,Yi Hao,Yihang Xiao,Xiaozhe Zhang,Xiayun Wei,Siyue Nie,Keren Zhang,Qiuyu Fu,Hao Chen,Niu Huang,Yan Ren,Mingxuan Wu,Billy Kwok Chong Chow,Xing Chen,Wenfei Jin,Fengchao Wang,Li Zhao,Feng Rao

DOI: https://doi.org/10.1016/j.molcel.2023.06.010

IF: 16

2023-01-01

Molecular Cell

Abstract:The diabetes-cancer association remains underexplained. Here, we describe a glucose-signaling axis that reinforces glucose uptake and glycolysis to consolidate the Warburg effect and overcome tumor suppression. Specifically, glucose-dependent CK2 O-GlcNAcylation impedes its phosphorylation of CSN2, a modification required for the deneddylase CSN to sequester Cullin RING ligase 4 (CRL4). Glucose, therefore, elicits CSN-CRL4 dissociation to assemble the CRL4COP1 E3 ligase, which targets p53 to derepress glycolytic enzymes. A genetic or pharmacologic disruption of the O-GlcNAc-CK2-CSN2-CRL4COP1 axis abrogates glucose-induced p53 degradation and cancer cell proliferation. Diet-induced overnutrition upregulates the CRL4COP1-p53 axis to promote PyMT-induced mammary tumorigenesis in wild type but not in mammary-gland-specific p53 knockout mice. These effects of overnutrition are reversed by P28, an investigational peptide inhibitor of COP1-p53 interaction. Thus, glycometabolism self-amplifies via a glucose-induced post-translational modification cascade culminating in CRL4COP1-mediated p53 degradation. Such mutation-independent p53 checkpoint bypass may represent the carcinogenic origin and targetable vulnerability of hyperglycemia-driven cancer.